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Summary
Dendritic spines show rapid motility and plastic mor-
phology, which may mediate information storage in
the brain. It is presently believed that polymerization/
depolymerization of actin is the primary determinant
of spine motility and morphogenesis. Here, we show
that myosin IIB, a molecular motor that binds and con-
tracts actin filaments, is essential for normal spine
morphology and dynamics and represents a distinct
biophysical pathway to control spine size and shape.
Myosin IIB is enriched in the postsynaptic density
(PSD) of neurons. Pharmacologic or genetic inhibition
of myosin IIB alters protrusive motility of spines, de-
stabilizes their classical mushroom-head morphol-
ogy, and impairs excitatory synaptic transmission.
Thus, the structure and function of spines is regulated
by an actin-based motor in addition to the polymeriza-
tion state of actin.
Introduction
Dendritic spines are small protrusions that serve as the
main site of excitatory synapses in the mammalian brain
(Harris and Kater, 1994; Hering and Sheng, 2001). Spines
exist in a variety of shapes and sizes, making them at-
tractive structural candidates for learning and memory
(Yuste and Bonhoeffer, 2001). In support of this idea,
long-term potentiation (LTP) has been associated with
increased spinogenesis and spine head growth,
whereas long-term depression (LTD) has been associ-
ated with spine shrinkage and retraction (Engert and
Bonhoeffer, 1999; Maletic-Savatic et al., 1999; Matsu-
zaki et al., 2001, 2004; Nagerl et al., 2004; Zhou et al.,
2004).
In addition to their morphological plasticity, spines
also display rapid motility, changing shape and size
over seconds to minutes in dissociated culture, slice,
*Correspondence: msheng@mit.eduand in vivo contexts (Fischer et al., 1998; Dunaevsky
et al., 1999; Lendvai et al., 2000). These changes include
the appearance and disappearance of filopodia, ‘‘amor-
phous’’ fluctuations of the spine head, elongation of the
spine neck, emergence of filopodia from the spine head,
and transient ‘‘kissing’’ of spine heads. These phenom-
ena are thought to be important in synaptogenesis as
well as in modulation of extant synapses (Bonhoeffer
and Yuste, 2002).
It is widely believed that both the heterogeneous mor-
phology and rapid motility of dendritic spines are deter-
mined by the polymerization and depolymerization of
actin (Fischer et al., 1998; Hering and Sheng, 2001; Bon-
hoeffer and Yuste, 2002; Star et al., 2002; Ackermann
and Matus, 2003; Okamoto et al., 2004). In other cell-bi-
ological contexts, however, actin dynamics are also reg-
ulated via a distinct and equally prominent mechanism:
myosin motors. The myosin superfamily is characterized
by the ability to bind actin and hydrolyze ATP in order to
translocate and maintain tension in actin filaments
(Sellers, 2000). Myosin II, a canonical member of this
family, is a hexameric polypeptide comprised of two
heavy chains and two pairs of regulatory light chains.
In vertebrates, myosin II is typically divided into two
classes: sarcomeric myosin II from skeletal muscle and
nonmuscle myosin II. Nonmuscle myosin II, in turn, ex-
ists in two isoforms, A and B. While most tissues express
equal amounts of both isoforms, neuronal tissue and
embryonic cardiomyocytes express predominantly the
B isoform (Kawamoto and Adelstein, 1991).
Nonmuscle myosin IIB (hereafter referred to as myo-
sin IIB) is required for cytokinesis and maintenance of
cortical tension in Dictyostelium, dorsal closure in
D. melanogaster, maintenance of embryonic polarity in
C. elegans, and neuronal migration and growth cone
motility in mice (De Lozanne and Spudich, 1987; Young
et al., 1993; Guo and Kemphues, 1996; Tullio et al., 1997).
Recent studies have revealed additional unexpected
roles for myosin IIB in mitotic spindle assembly and in
cell intercalation during development of the Drosophila
embryo (Rosenblatt et al., 2004; Bertet et al., 2004).
Proteomic analyses have uncovered the abundant
presence of the heavy chain of myosin IIB (MHCIIB)
in the postsynaptic density (PSD) fraction of rat brain
(Jordan et al., 2004; Peng et al., 2004). In this study,
we provide evidence that postsynaptic myosin IIB rep-
resents a means of regulating spine dynamics that is
mechanistically distinct from actin polymerization/de-
polymerization. We report the subcellular distribution
of myosin IIB in neurons and elucidate the function of
myosin IIB by pharmacological inhibition and molecular
genetic suppression with RNA interference (RNAi). Our
data indicate a critical role for myosin IIB in the morpho-
logical integrity of dendritic spines and in the mainte-
nance of synaptic transmission.
Results
To determine whether myosin IIB is enriched in the PSD,
we surveyed its abundance in subcellular fractions of rat
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176Figure 1. Blebbistatin Induces Loss of Mush-
room Spines and Formation of Filopodia-like
Protrusions
(A) DIV10 rat hippocampal neurons were
transfected with b-gal. Seven days later,
they were treated with nothing, DMSO,
(+)blebbistatin (100 mM), or blebbistatin (100
mM) for 30 min, and fixed and immunostained
for b-gal. Scale bar, 10 mm (low magnifica-
tion); 2 mm (high-magnification image of den-
drite). (B) Quantitation of protrusion length,
width, and density in neurons treated with
blebbistatin versus controls. *p < 0.001 cf. un-
treated neurons. Data represent mean 6
SEM.forebrain by immunoblotting (see Figure S1A in the Sup-
plemental Data available online). Myosin IIB was signifi-
cantly enriched in PSD fractions relative to crude synap-
tosomal fraction (P2), albeit to a lesser degree than the
NMDA receptor subunit NR2A, an established PSD
‘‘marker’’ protein (Figure S1A). Like NR2A, myosin IIB
was also abundant in P2 and P3 (light membrane) frac-
tions, suggesting partial association with membranes.
To investigate the subcellular distribution of myosin
IIB at the morphological level, we performed immunocy-
tochemistry on rat hippocampal neurons in dissociated
culture. In immature neurons (DIV8), myosin IIB immuno-
reactivity was present throughout the neuron but was
more concentrated in the cell body and proximal den-
drites (Figure S1B). In addition, myosin IIB staining
was more intense at dendritic branch points and at the
tips of dendrites and axons.
In more mature neurons (DIV18), myosin IIB dimin-
ished in the soma and localized primarily to dendrites,
where it accumulated in a punctate pattern on top of a
less intense diffuse staining (Figure S1C). Greater than
90% of myosin IIB dendritic puncta colocalized with
the PSD marker PSD-95, consistent with a clustering
of myosin IIB at synaptic sites. In addition, in roughly
half of these colocalizations, the myosin IIB puncta
was larger in size and extended past the PSD-95 margin
toward the dendritic shaft (Figure S1C). Therefore, the
zone of myosin IIB enrichment may extend past the
spine head into the neck of the spine.
To examine myosin IIB localization in vivo, we immu-
nostained hippocampal sections from w90-day-old
rats. Dense punctate labeling for myosin IIB filled the
apical and basal dendritic fields of the CA1 region but
was largely absent from the pyramidal cell soma (Fig-
ure S1D). The myosin IIB immunostaining showed ex-
tensive overlap with synaptophysin, a synaptic vesicle
protein. Overall, the immunocytochemistry results are
consistent with the biochemical fractionation data and
support the idea that myosin IIB is enriched in but not
exclusively localized to the postsynaptic compartment.
What is the function of myosin IIB in neurons? To ad-
dress this question, we utilized blebbistatin, a recently
discovered small molecule inhibitor of myosin II(Straight et al., 2003; Kovacs et al., 2004; Limouze
et al., 2004). Blebbistatin specifically inhibits the ATPase
activity of myosin II, trapping it in an ADP-bound state
that has low affinity for actin. At DIV17, control neurons
treated for 30 min with nothing, DMSO, or the inactive (+)
enantiomer of blebbistatin exhibited mostly mushroom-
shaped spines (Figure 1A). Neurons treated with active
blebbistatin (100 mM, 30 min) lost most of their mush-
room-headed spines and instead displayed long, thin fi-
lopodia-like processes that lacked heads (Figure 1A).
Accordingly, quantitative morphometry showed an in-
crease in mean length and a reduction in mean width
of dendritic protrusions (Figure 1B). The density of pro-
trusions per length of dendrite was also increased by
blebbistatin, relative to controls treated with nothing,
DMSO, or (+)blebbistatin (Figure 1B). In contrast to its ef-
fect on protrusion morphology, 100 mM blebbistatin did
not alter cell soma circumference, dendrite length, or
dendrite width (data not shown). In summary, pharma-
cological inhibition suggests that myosin IIB function
is required over the timeframe of minutes to maintain
the proper morphology of mature spines.
To confirm the veracity and specificity of the blebbis-
tatin effect, we used a molecular genetic approach
(RNAi) to suppress endogenous myosin IIB. Hippocam-
pal neurons transfected at DIV14 for 6 days with a
pSuper plasmid expressing small hairpin RNAs against
rat myosin IIB showed loss of myosin IIB immunofluo-
rescence (cell body intensity reduced to 30% of cell
body intensity in neighboring untransfected cells; Fig-
ures 2A and 2B). There was little change in myosin IIB
immunoreactivity in neurons transfected with empty
pSuper vector.
Myosin IIB-RNAi resulted in a spine phenotype similar
to that induced by 30 min blebbistatin treatment—
namely, a loss of mushroom-headed spines and a profu-
sion of irregular filopodia-like protrusions (Figures 2A
and 2B). Myosin IIB-RNAi caused an increase in mean
length and a decrease in mean width of dendritic protru-
sions relative to control transfected neurons (Figure 2B).
Unlike blebbistatin, however, RNAi-mediated inhibition
of myosin IIB did not affect the density of protrusions
significantly (Figure 2B). Myosin IIB RNAi did not alter
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177Figure 2. RNAi Knockdown of Myosin IIB In-
duces Loss of Mushroom Spines and Gener-
ation of Filopodia-like Protrusions
(A) DIV14 hippocampal neurons were trans-
fected for 6 days with b-gal plus pSuper vec-
tor or myosin IIB-RNAi construct, as indi-
cated, and stained for endogenous myosin
IIB (green) and b-gal (red). Arrows indicate
cell bodies of transfected cells. Rightmost
panels show high-magnification views of indi-
vidual transfected dendrites. Scale bar, 10 mm
(low magnification) and 2 mm (high magni-
fication). (B) Quantitation of myosin IIB im-
munofluorescence in the cell body, protrusion
length, protrusion width, and protrusion den-
sity in transfected neurons. Myosin IIB stain-
ing intensity in the cell body was compared
to untransfected neurons in the same field.
*p < 0.001 cf. pSuper transfected neurons.
Data represent mean 6 SEM.cell soma circumference, dendrite length, or dendrite
width (data not shown). The overall similarity of the phar-
macological and RNAi findings supports a specific role
for myosin IIB in the maintenance of mushroom-headed
spines in cultured neurons.
The above pharmacological and RNAi data imply that
myosin IIB is required to maintain mushroom-headed
spines while keeping filopodia in check, but this conclu-
sion is based on examination of separate populations of
fixed neurons. We therefore used time-lapse confocal
imaging of live neurons to address the following ques-
tion: does blebbistatin inhibition of myosin IIB cause
mushroom spines to directly transform into filopodia-
like protrusions, or are mushroom spines lost and sub-
sequently replaced by new filopodia?
Over a 70 min period (imaged once per minute), con-
trol spines treated with DMSO (added at the eleventh
minute) showed dynamic movements, as previously de-
scribed (Dailey and Smith, 1996; Dunaevsky et al., 1999;
Bonhoeffer and Yuste, 2002). Two major forms of motil-
ity were observed (Figure 3A and Movie S1). First, most
spines fluctuated in overall shape without any apparent
directionality (‘‘amorphous motility’’) (Figure 3A, ar-
rows). Second, some spines repeatedly extended and
retracted filopodia-like projections from their head
(‘‘protrusive’’ motility) (Figure 3A, arrowheads). Despitethe constant flux of these two types of motility, there
was a general maintenance of spine dimensions over
a timeframe of tens of minutes. During amorphous mo-
tility, the overall size of the spine remained the same de-
spite the rapid ‘‘morphing’’ of the head. Each filopodial
extension was almost always followed by a retraction
that reeled it back in. Thus, control spines appeared
much the same at the end of 70 min as they did at the
start (Figure 3A, bottom).
Blebbistatin caused marked changes in shape, size,
and motility of dendritic spines. During the 10 min prior
to drug application, spines displayed typical amorphous
and protrusive motility and retained their overall mush-
room-head morphologies (Figure 3B and Movie S2). Fol-
lowing blebbistatin (added at the eleventh minute),
spines adopted an altered protrusive motility. Rather
than extend filopodial processes from their spine heads
and then quickly retract them, blebbistatin-treated
spines kept extending these projections without any re-
traction, resulting in long thin processes extending from
the spine head (Figure 3B, arrowheads). Blebbistatin
also caused a new behavior. Rather than ‘‘morphing’’
around a stable baseline size, many mushroom heads
simply unfurled completely and transformed directly
into a filopodium (Figure 3B, arrows). After 70 min of
elapsed time, most of the original mushroom-shaped
Neuron
178Figure 3. Time-Lapse Imaging of Blebbistatin Effects on Dendritic Spines
(A and B) DIV10 neurons were transfected with dsRed for 7 days and then imaged on DIV17. Images were captured every minute. Timestamp
shows elapsed time in minutes (not all images are shown). In the first 10 min, neurons were left untreated. 100 mM blebbistatin (B) or DMSO
(A) was added at 11 min. Arrows indicate examples of ‘‘amorphous’’ motility in DMSO-treated neurons (A), and examples of unfurling of dendritic
spines into filopodia in blebbistatin-treated neurons (B). Arrowheads point to examples of filopodial extension/retraction in DMSO treated neu-
rons (A), and to filopodial extension from spine heads in blebbistatin-treated neurons (B). Scale bar, 2 mm. Bottom panels show higher-magni-
fication views of early and late time points (time stamp in minutes).spines showed completely changed morphology, either
with long filopodia-like protrusions extending from their
heads or being transformed into a filopodium (Figure 3B,
bottom). Time-lapse imaging revealed that filopodia
arose directly from spines, rather than de novo.
Given its role in the maintenance of dendritic spine
morphology, myosin IIB might be important for the in-
tegrity of the synapse. We tested this by immunostain-
ing for surface AMPA receptors in DIV17 dissociated
hippocampal neurons after 30 min treatment with 100
mM blebbistatin. Compared to control neurons treated
with DMSO, blebbistatin-treated neurons showed a re-
duction in linear density of AMPAR puncta, and those
puncta that remained were larger in size and irregularly
shaped (Figure S2). Parallel immunostaining experi-
ments showed no change in puncta density and size of
the presynaptic marker Bassoon following blebbistatin
treatment (30 min, 100 mM) (Figure S2). These findings
suggest that blebbistatin primarily affects synapse
structure on the postsynaptic side.
To examine a potential role for myosin IIB in synaptic
transmission, we tested the effects of blebbistatin on
AMPA receptor-mediated EPSCs recorded from CA1
neurons in acute rat hippocampal slices in response to
stimulation of Schaffer collateral inputs. In order to ex-
pose only postsynaptic cells to the drug, we applied
blebbistatin (50 mM) to CA1 neurons intracellularly via
the recording pipette. Starting w10 min after ‘‘break-
in,’’ blebbistatin caused a progressive decrease in am-plitude of EPSCs. Synaptic responses were depressed
to w60% after 60 min exposure to the drug (Figures
4A and 4B). Control neurons exposed to normal intracel-
lular solution, DMSO, or (+)blebbistatin in the recording
pipette maintained their AMPA-EPSCs over the same
timecourse (Figures 4A and 4B).
We also tested the effects of blebbistatin on mini-
EPSCs in dissociated hippocampal neurons. Neurons
filled intracellularly with 50 mM blebbistatin through the
recording pipette displayed a 36% decrease in fre-
quency and 27% decrease in amplitude of mini-EPSCs
after 50 min (Figures 4C and 4D). Neurons treated with
DMSO or (+)blebbistatin showed no change in fre-
quency or amplitude of mini-EPSCs.
Discussion
Spine morphology and motility are believed to be regu-
lated primarily by dynamic polymerization and depoly-
merization of the actin cytoskeleton. In support of this,
pharmacologic inhibition of actin polymerization with
cytochalasin-D inhibits spine motility in both dissoci-
ated and slice cultures (Fischer et al., 1998; Dunaevsky
et al., 1999). In addition, the F-actin/G-actin ratio and ac-
tin turnover in spines are regulated by activity (Star et al.,
2002; Okamoto et al., 2004).
A role for actomyosin contraction in spine dynamics
was initially excluded, based on pharmacological inhibi-
tion using 2,3 butanedione-monoxime (BDM); these
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179Figure 4. Inhibition of Excitatory Synaptic Transmission by Blebbistatin
(A) Blebbistatin (50 mM) was administered intracellularly via the recording pipette in CA1 pyramidal neurons of acute hippocampal slices, and
AMPA receptor-mediated EPSCs were recorded following Schaffer collateral stimulation (filled squares). Control slices were recorded with nor-
mal intracellular solution (open triangles), 0.1% DMSO (open squares), or 50 mM (+)blebbistatin (filled triangles) in the pipette. EPSC amplitude
was normalized to baseline. Data represent mean 6 SEM. (B) Representative EPSC traces from neurons treated with normal intracellular solu-
tion, DMSO, (+)blebbistatin, or active blebbistatin. Traces were averaged from 5 min of uninterrupted recording begun at indicated time points.
(C) Blebbistatin (50 mM) was administered intracellularly via the recording pipette into dissociated rat hippocampal neurons (DIV12–14), and mini-
EPSCs were recorded over 50 min. Control neurons were filled with either DMSO or 50 mM (+)blebbistatin. Mean amplitude and frequency of
mEPSCs recorded from 50–53 min after patching were normalized to mean mEPSC amplitude and frequency from 5–8 min. *p < 0.05 cf. 5
min time point. Data represent mean6 SEM. (D) Representative mEPSC recordings from dissociated hippocampal neurons filled intracellularly
with DMSO, (+)blebbistatin and active blebbistatin. Recordings are from 5–8 min after patching and from 50–53 min after patching.experiments showed no effect on morphology or motil-
ity of spines after drug treatment (Fischer et al., 1998).
BDM, however, was found in subsequent years to be
a poor inhibitor for several reasons. First, it has only
a low affinity for skeletal myosin II (KI w5 mM), and
against nonmuscle myosin II, it has no detectable inhib-
itory activity (Cramer and Mitchison, 1995; Cheung et al.,
2002). In addition, BDM nonspecifically affects other
proteins in the cell, including myosin II light chain kinase,
connexins, potassium channels, and L-type calcium
channels (Ostap, 2002). In terms of affinity and specific-
ity for nonmuscle myosin II, the recently discovered in-
hibitor blebbistatin appears to represent an improve-
ment over BDM. Blebbistatin has a KI of w2 mM, and
at 50 mM, inhibits both myosin IIA and IIB to w10% of
their maximal ATPase activity. In addition, blebbistatin
does not inhibit myosins I, V, or X (Straight et al., 2003).
In light of recent mass spectrometry data showing an
abundance of myosin heavy chain IIB in the PSD, we
sought to re-examine a potential role for this molecular
motor in spine dynamics (Jordan et al., 2004; Peng
et al., 2004). The enrichment of myosin IIB in the PSD
fraction and its immunocytochemical localization at syn-
apses is consistent with a role for this molecular motor in
shaping the dendritic spine head. In addition to its favor-able position at synaptic sites, loss-of-function experi-
ments—both pharmacologic and genetic—showed that
myosin IIB is in fact essential for spine morphology and
normal motility. Both blebbistatin and myosin IIB-RNAi
led to depletion of mushroom-type spines and their re-
placement with irregular filopodia-like processes. The
action of blebbistatin is rapid, with time-lapse studies re-
vealing profound alterations in spine morphology and
motility occurring within tens of minutes of drug applica-
tion. Blebbistatin-induced inhibition of myosin IIB also
appears to have functional consequences, resulting in
a depression of EPSCs and a decrease in both frequency
and amplitude of mini-EPSCs; these effects are more
likely secondary to the disruption of synaptic architec-
ture rather than reflecting a direct role of myosin IIB in
synaptic transmission.
Blebbistatin can inhibit both myosin IIA and -B, and its
neuronal effects could hypothetically be due to inhibi-
tion of either or both. We believe that inhibition of myosin
IIB most likely underlies the observed phenotype be-
cause the IIB isoform is expressed at higher levels in
neurons than IIA (Kawamoto and Adelstein, 1991; data
not shown), and because RNAi of myosin IIB alone in-
creases protrusion length and decreases protrusion
width, similarly to blebbistatin. Nevertheless, it should
Neuron
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osin IIA in regulation of spine morphology.
In many other cellular contexts, myosin IIB serves to
contract or maintain tension in actin filament networks.
For example, this contractile function is required for cy-
tokinesis as well as cortical tension in Dictyostelium
(Knecht and Loomis, 1987; Pasternak et al., 1989). In
Saccharomyces cerevisiae, ablation of myosin II results
in aberrant cell wall formation at the mother/bud neck,
disrupting cell division (Watts et al., 1987). How do these
well-conserved functions shed light on the dendritic
spine phenotypes caused by myosin IIB loss of func-
tion? The volatile projection of filopodia from spine
heads could be explained if myosin IIB is required to
maintain the integrity of the mushroom surface by gen-
erating tangential forces at the spine head membrane.
This ‘‘surface tension’’ could counteract the forces of
polymerizing actin that act outwardly in a perpendicular
direction to the membrane surface to extend filopodia.
The unraveling of a mushroom into a filopodium, in turn,
could be a more severe consequence of the loss of tan-
gential surface tension in the bulbous spine head. Fur-
ther studies need to be performed to precisely describe
where and how myosin IIB is acting biophysically.
As a regulator of spine morphology and motility, myo-
sin IIB possesses attractive properties. Its actin binding
activity is highly regulated, primarily by phosphorylation
of the Ser19 residue on its regulatory light chain, and this
light chain has been shown to bind directly to the C ter-
mini of the NR1 and NR2 subunits of NMDA receptors
(Suzuki et al., 1978; Amparan et al., 2005). The phos-
phorylation state of myosin light chain is controlled by
signaling pathways that are prominent in neurons and
in the PSD in particular. For example, myosin light chain
kinase (MLCK), which phosphorylates and thereby acti-
vates myosin IIB, is stimulated by Ca2+/calmodulin
(Goeckeler and Wysolmerski, 1995). In addition, P21-
associated kinase (PAK), and Rho-associated kinase
(ROCK) have been shown to directly phosphorylate my-
osin IIB (Chew et al., 1998; Amano et al., 1998) and to
regulate spine morphology (Hayashi et al., 2004).
ROCK is particularly compelling because it is a primary
effector of RhoA, a small GTPase with profound conse-
quences on neuronal and spine morphology. Constitu-
tively active RhoA results in marked loss of dendritic
spines when transfected into rat hippocampal slices
(Nakayama et al., 2000), and this phenotype could per-
haps be explained in part by a Rho-ROCK-myosin cas-
cade, culminating in myosin contraction of actin fila-
ments and retraction of spines. Such a model is
admittedly simplistic, as Rho and ROCK can influence
other proteins as well. In growth cones of retinal gan-
glion neurons, for example, ROCK regulates filopodial
extension via ADF/cofilin rather than myosin IIB, sug-
gesting that the reduction of spines caused by active
RhoA could be mediated by inhibition of ADF/cofilin as
well as through myosin IIB activation (Gehler et al.,
2004).
In conclusion, our findings suggest that spine mor-
phology and motility are not controlled solely by actin
polymerization/depolymerization, but are also critically
dependent on the molecular motor myosin IIB. Because
it can reversibly bind and contract actin, and because it
can be bidirectionally regulated, myosin IIB appears tobe a novel and potent means of controlling the dynamic
structure of dendritic spines.
Experimental Procedures
Antibodies and Drugs
The following antibodies have been described previously: rabbit
NR2A (Sheng et al., 1994) and monoclonal PSD95 (Hering and
Sheng, 2003). The following antibodies were purchased commer-
cially: MHCIIB (Covance, Berkeley, CA); b-galactosidase (Promega,
Madison, WI); GluR1 (Calbiochem, Darmstadt, Germany); Bassoon
(StressGen, Sidney, Canada). Blebbistatin was purchased from Toc-
ris (Ellisville, MO).
DNA Constructs
The following oligonucleotides (targeted to nts 4362-4380 of rat
MHCIIB) were annealed and cloned into pSuper vector to make
the RNAi construct against MHCIIB: 50-gatccccgaagccaagaagaa
actgcttcaagagagcagtttcttcttggcttctttttggaaa-30 and 50-agctttccaaa
aagaagccaagaagaaactgctctcttgaagcagtttcttcttggcttcggg-30. mRFP
was cloned into pGWI vector. DsRed2 expression plasmid was
from Clontech.
Subcellular and PSD Fractionation
Two adult rat forebrains were fractionated as described (Huttner
et al., 1983). Forebrains were homogenized and spun at 1400 3 g,
and the supernatant (S1) was set aside. The pellet (P1) was homog-
enized and spun at 7103 g. The supernatant was pooled with S1and
spun at 13,800 3 g. The supernatant (S2) was set aside. The pellet
(P2) was layered onto a discontinuous sucrose gradient and spun
at 82,500 3 g. The synaptosomal fraction was isolated from the
1.0/1.2 M sucrose interface and spun at 32,800 3 g, and the pellet
(PSDI) was resuspended. PSDII and -III were obtained by Triton
and Sarcosyl extractions of the PSDI pellet, respectively. These pel-
lets were spun down at 201,800 3 g. S2 was also spun down at this
stage to produce S3 and P3.
Neuronal Culture, Immunostaining, Drug Treatment,
and Transfection
Hippocampal neurons were dissected from E20 Sprague-Dawley rat
embryos, plated onto coated glass coverslips (30 mg/mL PDL and
2.5 mg/mL laminin), and cultured in Neurobasal medium (Invitrogen)
with B27 (Invitrogen), 0.5 mM glutamine, and 12.5 mM glutamate.
For MHCIIB, PSD95, and Bassoon staining, neurons were fixed in
100% methanol for 10 min at 220ºC. Neurons in the blebbistatin tri-
als were fixed in 4% PFA/4% sucrose at RT for 10 min. RNAi trans-
fected neurons were fixed in 4% PFA/4% sucrose for 3 min at RT,
followed by 10 min in 100% methanol at 220ºC. For AMPAR stain-
ing, neurons were incubated in GluR1 antibody (diluted in DMEM)
at 37ºC for 10 min and fixed in 4% PFA/4% sucrose for 8 min at
RT. Immunostaining was performed as previously described (Sala
et al., 2001). Blebbistatin was administered to neurons by diluting
50 mM stock 1:500 into conditioned neuron media, for a final con-
centration of 100 mM. All transfections were done using calcium
phosphate (Sala et al., 2001). For the blebbistatin trials, neurons
were transfected with 4 mg b-gal/well. For RNAi experiments, each
well of neurons was cotransfected with 2.5 mg of b-gal and 7.5 mg
of pSuper or MHCIIB RNAi.
Microscopy and Quantitation
Fixed neurons were imaged with an LSM510 confocal microscope
system (Zeiss, Oberkochen, Germany) and an Axioplan microscope
(Zeiss). A 633 oil-immersion lens (N.A. 1.40) was used. Except for
neurons costained for PSD95 and MHCIIB, each image consisted
of a z-stack projected into one image. Live imaging was performed
using Multi-time software (Zeiss) with a Pascal confocal system
(Zeiss) and an Axiovert microscope (Zeiss), using a 1003 oil immer-
sion lens and w3.53 digital zoom. Cells were treated with 10 mM
HEPES (pH 7.4) and imaged at 37ºC/5% CO2.
Morphometric measurements were performed using MetaMorph
Software (Universal Imaging, West Chester, PA). For colocalization
quantification, the PSD95 and MHCIIB channels were parsed into
Myosin IIB and Dendritic Spine Morphology
181separate images. A threshold level for each channel was manually
set in order to exclude diffuse background staining, leaving only
the puncta visible; the same threshold level was used for each neu-
ron. The two thresholded images—each in a different color—were
overlaid upon each other and the percentage of puncta overlapping
with each other was manually counted. Ten neurons were used for
this analysis.
In the blebbistatin experiments, 10 to 15 neurons were imaged for
each of the four conditions. For each neuron, five 50–70 mm dendritic
segments were chosen for spine morphometric analysis. Protru-
sions were defined as being >0.5 mm in length. Protrusion length
was defined as the distance from the base to the tip of the protru-
sion; width was defined as the maximum distance perpendicular
to the long axis of the protrusion. For each neuron, all the spine
length, width, and density values were averaged into a single value;
each cell was represented by one spine length, width, and density.
The values for all neurons within a condition were then used to cal-
culate a mean and SEM. For the RNAi experiments, 10 to 15 neurons
were imaged for pSuper and MHCIIB RNAi transfected neurons. The
cell soma was manually traced using the immunofluorescence of the
transfected marker bgal; a projection constructed from a stack of
confocal images was used for each neuron. Once the tracing was
finished, the average intensity of the traced area was quantified in
the MHCIIB channel. Cell body immunofluorescence was quantified
by comparing the average intensity of the transfected neuron’s cell
soma to the soma of an untransfected neighbor in the same visual
field. Spine morphometric analysis in the RNAi experiments was per-
formed in the same manner as in the blebbistatin experiments. For
AMPAR-mediated EPSC experiments, 6 to 12 neurons were used
for each condition. For mEPSC experiments, 5 to 7 neurons were
used for each condition.
Electrophysiology
Hippocampal slices were prepared from 19- to 23-day-old Sprague-
Dawley rats. 400 mm coronal brain slices were cut using a vibrating
blade microtome in ice-cold ACSF containing (in mM) 126 NaCl,
2.5 KCl, 1 MgCl2, 1 CaCl2, 1.25 KH2PO4, 26 NaHCO3, and 20 glucose
that was bubbled with 95% O2/5% CO2. Slices were recovered at
34ºC for 1.5 hr and maintained at RT. Slices were perfused at RT
with carbogenated ACSF during recording. Whole-cell recordings
of CA1 neurons were performed with a MultiClamp 700A amplifier
(Axon Instruments, Foster City, CA) at holding potential –60 mV.
The recording pipettes (6–8 MU) were filled with pH 7.2 solution con-
taining (in mM) 132.5 Cs-gluconate, 17.5 CsCl, 2 MgCl2, 0.5 EGTA, 10
HEPES, 4 ATP, and 5 QX-314. Cells were excluded if >20% change in
the series or input resistance occurred. EPSCs were evoked every
20s by stimulating the Schaffer collateral-commissural pathway
via a constant current pulse (0.05 ms) delivered in the presence of
bicuculline methiodide (10 mM) in ACSF.
For mEPSCs, DIV12-14 cultured neurons were perfused with
ECS containing (in mM) 140 NaCl, 5.4 KCl, 1 MgCl2, 1.3 CaCl2, 25
HEPES, and 30 glucose (pH 7.35), in addition to bicuculline
(10 mM) and tetrodotoxin (0.5 mM). Whole-cell patch-clamp record-
ings were performed at a holding membrane potential of 260 mV
with an AXOPATCH-1D amplifier (Axon). Recordings were low-pass
filtered at 2 kHz, sampled at 10 kHz, and stored as data files using
Clampex 8.0 (Axon). Recordings where the series resistance varied
more than 10% were rejected.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/49/2/175/DC1/.
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